Next Article in Journal
Optimization of Micellar Electrokinetic Chromatography Method for the Simultaneous Determination of Seven Hydrophilic and Four Lipophilic Bioactive Components in Three Salvia Species
Previous Article in Journal
Ultrasound-Assisted Aqueous Two-Phase System for Extraction and Enrichment of Zanthoxylum armatum Lignans
Article Menu

Export Article

Open AccessArticle
Molecules 2015, 20(8), 15287-15303; doi:10.3390/molecules200815287

Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors

1
Chemistry Department, Faculty of Science, Fayoum University, El-Fayoum 63551, Egypt
2
Department of Chemistry, Faculty of Science, Bani Suef University, Bani Suef 62111, Egypt
3
Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt
4
Research Unit, Saco Pharm. Co., 6th of October City 68330, Egypt
5
Department of Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt
*
Author to whom correspondence should be addressed.
Academic Editor: Jean Jacques Vanden Eynde
Received: 22 July 2015 / Revised: 2 August 2015 / Accepted: 6 August 2015 / Published: 21 August 2015
(This article belongs to the Section Organic Synthesis)
View Full-Text   |   Download PDF [1444 KB, uploaded 21 August 2015]   |  

Abstract

The usefulness of non-steroidal anti-inflammatory drugs (NSAIDs) is hampered by their gastrointestinal side effects. Non-selective cyclooxygenases inhibitors interfere with both COX-1 and COX-2 isozymes. Since COX-1 mediates cytoprotection of gastric mucosa, its inhibition leads to the undesirable side effects. On the other hand, COX-2 is undetectable in normal tissues and selectively induced by inflammatory stimuli. Therefore, it is strongly believed that the therapeutic benefits derive from inhibition of COX-2 only. The presence of a strong connection between reported COX-2 inhibitors and cardiac toxicity encourages medicinal chemists to explore new scaffolds. In the present study, we introduced imidazopyrazolopyridines as new potent and selective COX-2 inhibitors that lack the standard pharmacophoric binding features to hERG. Starting from our lead compound 5a, structure-based drug-design was conducted and more potent analogues were obtained with high COX-2 selectivity and almost full edema protection, in carrageenan-induced edema assay, in case of compound 5e. Increased bulkiness around imidazopyrazolopyridines by adding a substituted phenyl ring(s) afforded less active compounds. View Full-Text
Keywords: aminopyrazolopyridine; anti-inflammatory; cyclooxygenase; hydrazonyl halides; selective inhibitors aminopyrazolopyridine; anti-inflammatory; cyclooxygenase; hydrazonyl halides; selective inhibitors
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Badrey, M.G.; Abdel-Aziz, H.M.; Gomha, S.M.; Abdalla, M.M.; Mayhoub, A.S. Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors. Molecules 2015, 20, 15287-15303.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top